DEERFIELD MANAGEMENT COMPANY, L.P. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001009258
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 427 positions · Total reported value $5.27B · Top-10 concentration 54.1% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 38.6% · 10 new · 12 cut · 12 exited
Active Share (vs S&P 500): 99.6% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +17.1% · vs SPY +2.2% · Prev Value $7.59B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2024 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. disclosed 427 equity positions with a combined reported value of $5.27B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 54.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were NUVL ($1.52B), VTRS ($227.43M), CNC ($175.70M). By sector, the heaviest allocations are Health Care 53.4%, Technology 2.6%. Versus the prior quarter, allocation shifted toward Technology (+2.3pp), Consumer Staples (+1.2pp) and away from Other (-4.4pp).
Versus the prior quarter, DEERFIELD MANAGEMENT COMPANY, L.P. opened 10 new positions, trimmed 12 and fully exited 12, a turnover rate of 38.6% of positions. The portfolio's overlap with the prior quarter was 35% of names.
The largest new positions opened in Q2 2024 were WAY ($106.47M), GILD ($102.30M), MIRM ($93.83M).
Of the 12 positions fully exited versus the prior quarter, the largest were FUSN ($136.47M), DCPH ($80.65M), SWTX ($63.16M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- WAY WAYSTAR HLDG CORP · $106.47M
- GILD GILEAD SCIENCES INC · $102.30M
- MIRM MIRUM PHARMACEUTICALS INC · $93.83M
- CVS CVS HEALTH CORP · $57.58M
- ALNY ALNYLAM PHARMACEUTICALS INC · $29.11M
- MREO MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS · $24.16M
- PACS PACS GROUP INC · $19.58M
- FHTX FOGHORN THERAPEUTICS INC · $14.48M
Fully Exited (vs previous quarter)
- FUSN FUSION PHARMACEUTICALS INC · prev qtr: $136.47M
- DCPH DECIPHERA PHARMACEUTICALS IN · prev qtr: $80.65M
- SWTX SPRINGWORKS THERAPEUTICS INC · prev qtr: $63.16M
- VKTX VIKING THERAPEUTICS INC · prev qtr: $38.01M
- VSTM VERASTEM INC · prev qtr: $18.15M
- QDEL QUIDELORTHO CORP COM · prev qtr: $16.68M
- GH GUARDANT HEALTH INC · prev qtr: $16.33M
- ENGN ENGENE THERAPEUTICS INC · prev qtr: $13.56M
Insider Transactions (Form 4)
Latest DEERFIELD MANAGEMENT COMPANY, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-15 | D | Nuvalent, Inc. | 3,444 | $124.00 | SEC filing |
| 2026-07-15 | U | Nuvalent, Inc. | 5,146 | $124.00 | SEC filing |
| 2026-07-15 | D | Nuvalent, Inc. | 650,000 | $124.00 | SEC filing |
| 2026-07-15 | D | Nuvalent, Inc. | 8,299,225 | $124.00 | SEC filing |
| 2026-06-16 | Award | Nuvalent, Inc. | 3,444 | — | SEC filing |
| 2026-06-11 | Conversion | Parabilis Medicines, Inc. | 407,132 | — | SEC filing |
| 2026-06-11 | Conversion | Parabilis Medicines, Inc. | 260,992 | — | SEC filing |
| 2026-06-11 | Conversion | Parabilis Medicines, Inc. | 149,238 | — | SEC filing |
Fund Profile
Deerfield Management Company, L.P. is a New York-based hedge fund founded by Marianne and James Chadwin, known for its quantitative and fundamental research approach focused primarily on healthcare and biotechnology investments.
Investment Approach
Combines quantitative analysis with fundamental research
Specializes in healthcare and biotechnology sectors
Utilizes both public and private investment strategies
Asset Classes & Strategy
Primarily focused on long/short equity positions
Specializes in healthcare and biotechnology investments
Also invests in other sectors with strong fundamental research
Key Personnel
Marianne Chadwin (Co-founder)
James Chadwin (Co-founder)
Team of experienced portfolio managers and researchers
AUM & Performance
Manages approximately $19.1 billion in assets under management
Performance data not publicly disclosed
All information is based on publicly available SEC filings and company disclosures.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
19.99M | $1.52B | 28.77% | Hold | |
| 2 |
|
21.40M | $227.43M | 4.32% | Hold | |
| 3 |
|
2.65M | $175.70M | 3.33% | Add | |
| 4 |
|
2.75M | $162.68M | 3.09% | Add | |
| 5 |
|
21.23M | $153.93M | 2.92% | Hold | |
| 6 |
|
9.13M | $141.38M | 2.68% | Hold | |
| 7 |
|
13.26M | $132.58M | 2.52% | Hold | |
| 8 |
|
3.09M | $119.93M | 2.27% | Hold | |
| 9 |
|
4.71M | $111.99M | 2.12% | Add | |
| 10 |
|
5.41M | $111.42M | 2.11% | Hold | |
| 11 |
|
6.96M | $110.10M | 2.09% | Reduce | |
| 12 |
|
15.61M | $106.63M | 2.02% | Hold | |
| 13 |
|
4.95M | $106.47M | 2.02% | New | |
| 14 |
|
1.49M | $102.30M | 1.94% | New | |
| 15 |
|
691.00K | $95.13M | 1.80% | Hold | |
| 16 |
|
11.08M | $94.27M | 1.79% | Hold | |
| 17 |
|
70.00M | $93.83M | 1.78% | New | |
| 18 |
|
6.37M | $86.01M | 1.63% | Add | |
| 19 |
|
10.90M | $85.25M | 1.62% | Add | |
| 20 |
|
2.10M | $73.63M | 1.40% | Reduce | |
| 21 |
|
4.00M | $57.90M | 1.10% | Hold | |
| 22 |
|
975.00K | $57.58M | 1.09% | New | |
| 23 |
|
3.28M | $57.21M | 1.08% | Add | |
| 24 |
|
1.58M | $52.77M | 1.00% | Add | |
| 25 |
|
2.87M | $51.77M | 0.98% | Hold | |
| 26 |
|
8.14M | $50.28M | 0.95% | Add | |
| 27 |
|
594.00K | $47.73M | 0.91% | Add | |
| 28 |
|
1.02M | $46.12M | 0.88% | Add | |
| 29 |
|
5.00M | $44.58M | 0.85% | Hold | |
| 30 |
|
631.26K | $43.76M | 0.83% | Add | |
| 31 |
|
1.47M | $42.77M | 0.81% | Hold | |
| 32 |
|
151.71K | $41.43M | 0.79% | Hold | |
| 33 |
|
2.92M | $40.28M | 0.76% | Add | |
| 34 |
|
1.41M | $34.96M | 0.66% | Hold | |
| 35 |
|
2.73M | $34.08M | 0.65% | Hold | |
| 36 |
|
844.41K | $33.16M | 0.63% | Reduce | |
| 37 |
|
3.74M | $31.56M | 0.60% | Add | |
| 38 |
|
119.80K | $29.11M | 0.55% | New | |
| 39 |
|
2.82M | $28.09M | 0.53% | Reduce | |
| 40 |
|
1.40M | $26.27M | 0.50% | Add | |
| 41 |
|
6.71M | $24.16M | 0.46% | New | |
| 42 |
|
112.43K | $22.69M | 0.43% | Add | |
| 43 |
|
3.80M | $22.45M | 0.43% | Reduce | |
| 44 |
|
7.20M | $22.24M | 0.42% | Add | |
| 45 |
|
1.17M | $21.28M | 0.40% | Hold | |
| 46 |
|
663.85K | $19.58M | 0.37% | New | |
| 47 |
|
240.22K | $19.29M | 0.37% | Hold | |
| 48 |
|
874.61K | $19.04M | 0.36% | Reduce | |
| 49 |
|
869.25K | $16.70M | 0.32% | Add | |
| 50 |
|
4.13M | $15.75M | 0.30% | Hold | |
FAQ
What did DEERFIELD MANAGEMENT COMPANY, L.P. buy in 2024-Q2?
In its 2024-Q2 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. reported 427 equity positions worth $5.27B in aggregate; its largest disclosed positions were NUVL ($1.52B), VTRS ($227.43M), CNC ($175.70M).
How large is DEERFIELD MANAGEMENT COMPANY, L.P.'s portfolio?
DEERFIELD MANAGEMENT COMPANY, L.P. reported $5.27B of long equity holdings across 427 positions as of 2024-Q2. Top-10 holdings account for 54.1% of reported value.
What is DEERFIELD MANAGEMENT COMPANY, L.P.'s investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.